Revvity Is Maintained at Outperform by Leerink Partners
Leerink Partners Maintains Revvity(RVTY.US) With Buy Rating, Raises Target Price to $135
Barclays Maintains Revvity(RVTY.US) With Buy Rating, Maintains Target Price $140
Revvity Analyst Ratings
Barclays Upgrades Revvity(RVTY.US) to Buy Rating, Raises Target Price to $140
Barclays Upgrades Revvity to Overweight, Price Target Is $140
Nephron Initiates Revvity(RVTY.US) With Hold Rating, Announces Target Price $130
Revvity (RVTY) Gets a Hold From Wells Fargo
Jefferies Maintains Revvity(RVTY.US) With Hold Rating, Raises Target Price to $130
Revvity Initiated at Equal-Weight by Wells Fargo
Revvity Analyst Ratings
Wells Fargo Initiates Coverage On Revvity With Equal-Weight Rating, Announces Price Target of $130
Analysts Have Conflicting Sentiments on These Healthcare Companies: Revvity (RVTY), PTC Therapeutics (PTCT) and Tectonic Therapeutic (TECX)
Revvity Price Target Raised to $145.00/Share From $135.00 by Citigroup
TD Cowen Adjusts Price Target on Revvity to $141 From $130
A Quick Look at Today's Ratings for Revvity(RVTY.US), With a Forecast Between $125 to $145
B of A Securities Maintains Neutral on Revvity, Raises Price Target to $127
Revvity's Balanced Performance Amidst Market Challenges: A Hold Recommendation With Updated Price Objective
Barclays Sticks to Their Hold Rating for Revvity (RVTY)
Jefferies Maintains Hold on Revvity, Raises Price Target to $125